UBS raises LLY target to $1,425 from $1,250UBS 上调目标价 礼来 (LLY)：$1,250 → $1,425
Target Price Revision Details
UBS raised its per-share price target for Eli Lilly (NYSE: LLY) to $1,425 from $1,250 on July 13, 2026, marking a 14.0% upward adjustment. Eli Lilly has a current market capitalization of approximately $1.14 trillion, and the stock closed at $1,185.08 on the prior trading day, representing a 0.29% daily decline.
Analyst Sentiment Shift
This adjustment only revises the price target without adjusting Eli Lilly’s formal investment rating, representing a standalone valuation model update from UBS. The move reflects the firm’s upward revision of its expectations for Eli Lilly’s future business growth or cash flow prospects, and does not signal a full investment rating upgrade.
Cross-Reference to Fundamentals and Insider Activity
We can validate this revision using public filings and performance data: Eli Lilly’s Q1 2026 earnings report, released April 30, 2026, showed adjusted EPS of $8.55, beating consensus estimates of $6.97, and total revenue of $19.799 billion, exceeding the $17.819 billion consensus forecast, marking multiple consecutive quarters of earnings and revenue beats. Additionally, a December 31, 2025, 13F filing shows Eli Lilly has 4,499 institutional shareholders, an increase of 466 from prior periods, with institutional holdings covering 88.2% of the company’s floating stock, reflecting broad institutional confidence. On June 11, 2026, EVP and President of U.S. and Global Capabilities Ilya Yuffa sold 2,500 shares at $1,150.77 for a total of $2,876,925, a routine insider share adjustment with no negative signaling.
What This Signal Does Not Prove
1. This adjustment represents only UBS’s individual valuation judgment, not an official investment recommendation or target price from InvestLog, and does not reflect broad market consensus.
2. The revision does not disclose specific business driving details, such as new drug development progress or regulatory policy changes, and is based solely on UBS’s internal valuation model updates.
3. The signal cannot directly predict the short-term price movement of Eli Lilly’s stock, only reflecting a single firm’s revised long-term valuation.
目标价调整详情
瑞银（UBS）于2026年7月13日上调礼来（NYSE: LLY）的每股目标价，从1250美元提升至1425美元，上调幅度达14.0%。当前礼来市值约11400亿美元，当日该股收盘价为1185.08美元，较前一交易日下跌0.29%。
分析师情绪变化
此次调整仅涉及目标价修正，未同步调整礼来的具体投资评级，属于单一机构的估值模型更新。该动作反映瑞银对礼来未来业务增长或现金流前景的乐观预期调整，并未传递全面投资评级升级的信号。
基本面交叉验证
我们可以结合公开财报与机构持仓数据验证这一调整的合理性：2026年4月30日公布的礼来2026年第一季度财报显示，当季实际每股收益为8.55美元，超出市场预期的6.97美元；实际营收197.99亿美元，高于市场预期的178.19亿美元，连续多个季度实现业绩超预期。此外，截至2025年12月31日的13F文件显示，礼来的机构持仓股东达4499家，较此前增加466家，机构持股覆盖88.2%的流通股，显示市场机构对该股的长期认可度较高。2026年6月11日，礼来执行副总裁Ilya Yuffa出售2500股公司股票，成交价1150.77美元，总金额约287.69万美元，属于常规高管持股调整，未传递负面信号。
该信号未覆盖的内容
1. 此次调整仅为瑞银一家机构的估值判断，并非InvestLog发布的官方投资建议或目标价，不代表全市场共识。
2. 该调整未披露具体的业务驱动细节（如新药研发进展、医保政策变化等），仅基于瑞银内部估值模型更新。
3. 无法直接推断该股未来短期价格走势，仅反映单一机构对其长期估值的修正。
This analysis was generated by InvestLog AI based on SEC filings, Form 4 insider transactions, Form 144 planned-sale notices, 13F institutional holdings, analyst ratings, and market data. It is for informational purposes only and does not constitute investment advice.这篇研究由 InvestLog AI 基于 SEC 披露、Form 4 内部人交易、Form 144 计划减持、13F 机构持仓、分析师评级和市场数据生成。内容仅供参考，不构成投资建议。